beta

AKTX

Akari Therapeutics Plc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity.

Market Cap: 68.1 Million

Primary Exchange: NASDAQ CAPITAL MARKET

Website: akaritx.com

Shares Outstanding: 38.5 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.218764291846338

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 2437 trading days

From: 2014-01-15 To: 2021-06-18

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
2015-09-17 10.0 1.0 10.0
Data provided by IEX Cloud